Brain atrophy screening


QUIBIM has developed a noninvasive post-processing application to calculate the volume of brain tissues and their regions. The tool calculates the volume of gray matter, white matter, cerebrospinal fluid and their distribution, as well as the parenchima fraction.
Product specifications Information source: Vendor
Last updated: March 10, 2020
Product name Brain atrophy screening
Company QUIBIM
Subspeciality Neuro
Modality MR
Disease targeted Brain atrophy, Alzheimer's, Dementia
Key-features the volume of grey matter, white matter, cerebrospinal fluid and their distribution, parenchyma fraction
Suggested use Without interference of a radiologist: AI-only diagnosis
Data characteristics
Population Patients with neurological degenerative disease
Input MRI T1 GRE 3D T1 Fast Gradient Echo
Input format
Output One-page structured report: normative bars of brain (sub)region volume
Output format DICOM Secondary Capture / PDF
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based, Hybrid solution
Trigger for analysis Automatically, right after the image acquisition
Processing time > 10 minutes
Certified, Class IIa
No or not yet
Market presence
On market since 01-2019
Distribution channels
Countries present (clinical, non-research use) 8
Paying clinical customers (institutes) 5+
Research/test users (institutes) <5
Pricing model License
Based on Number of installations, Number of analyses
Peer reviewed papers on performance
Non-peer reviewed papers on performance
Other relevant papers Magraner MJ, Bosca I, Simó-Castello M, García-Martí G, Alberich-Bayarri A, Álvarez-Cermeño JC, Martí-Bonmatí L, Villar LM, Casanova B (2012). Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology. 2012 Jan; 54(1): 5-12.